Published in Am J Psychiatry on July 01, 2013
D-Cycloserine Enhancement of Exposure in Social Phobia | NCT00633984
A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry (2014) 4.25
Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry (2014) 1.48
From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders. Neurobiol Learn Mem (2013) 1.19
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res (2013) 1.09
D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol (2013) 1.04
D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord (2013) 0.98
HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand? Biochem Soc Trans (2014) 0.95
Brain connectomics predict response to treatment in social anxiety disorder. Mol Psychiatry (2015) 0.95
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther (2014) 0.92
Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors. Front Psychiatry (2014) 0.91
Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety (2013) 0.83
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Expert Rev Neurother (2014) 0.82
Exercise Augmentation of Exposure Therapy for PTSD: Rationale and Pilot Efficacy Data. Cogn Behav Ther (2015) 0.82
D-cycloserine to enhance extinction of cue-elicited craving for alcohol: a translational approach. Transl Psychiatry (2015) 0.81
The role of the medial prefrontal cortex in regulating social familiarity-induced anxiolysis. Neuropsychopharmacology (2013) 0.80
D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety (2014) 0.80
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry (2015) 0.79
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. Int J Neuropsychopharmacol (2016) 0.79
Harnessing N-methyl-d-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studies. Am J Psychiatry (2013) 0.79
D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry (2015) 0.77
Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials (2015) 0.76
Psychological treatment of social anxiety disorder improves body dysmorphic concerns. J Anxiety Disord (2013) 0.76
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis. PLoS One (2017) 0.75
Evaluating changes in judgmental biases as mechanisms of cognitive-behavioral therapy for social anxiety disorder. Behav Res Ther (2015) 0.75
Neuroenhancement of Exposure Therapy in Anxiety Disorders. AIMS Neurosci (2015) 0.75
Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behav Res Ther (2016) 0.75
The effect of D-cycloserine on social anxiety treatment using a behavioral outcome measure and a post-session administration strategy. Behav Anal (Wash D C) (2016) 0.75
Looking beyond Fear and Extinction Learning: Considering Novel Treatment Targets for Anxiety. Curr Behav Neurosci Rep (2014) 0.75
Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci (2015) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 36.40
Social phobia. Mod Probl Pharmacopsychiatry (1987) 6.76
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry (2004) 5.26
Behavioral and neural analysis of extinction. Neuron (2002) 4.53
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci (2002) 4.52
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry (2008) 3.63
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci (1992) 3.40
Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol (2003) 3.22
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry (2007) 3.03
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry (2006) 2.77
Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry (2009) 2.43
Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci (2003) 2.39
Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry (1998) 2.31
A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry (2012) 2.12
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry (2008) 2.03
Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry (2004) 1.94
A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry (2010) 1.78
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol (2007) 1.46
A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res (2006) 1.44
Role of the amygdala in fear extinction measured with potentiated startle. Ann N Y Acad Sci (2003) 1.40
Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA (1998) 1.26
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry (2010) 1.20
Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry (1992) 1.19
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther (2010) 1.18
D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res (2011) 1.06
Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry (2001) 1.05
Cognitive enhancers for anxiety disorders. Pharmacol Biochem Behav (2010) 1.04
D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Pharm Des (2012) 0.99
Extinction retention predicts improvement in social anxiety symptoms following exposure therapy. Depress Anxiety (2009) 0.89
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry (2008) 6.24
Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry (2006) 3.70
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry (2008) 3.64
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry (2014) 3.27
A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol (2009) 3.26
Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry (2005) 3.19
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res (2012) 3.06
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Complicated grief and related bereavement issues for DSM-5. Depress Anxiety (2011) 2.77
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry (2006) 2.77
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychother Psychosom (2014) 2.41
Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: Implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord (2010) 2.23
Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med (2004) 2.16
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther (2005) 2.08
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2004) 2.04
Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry (2013) 2.00
Computer-assisted cognitive therapy for depression: maintaining efficacy while reducing therapist time. Am J Psychiatry (2005) 1.97
Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol (2012) 1.94
Cross-cultural differences in somatic presentation in patients with generalized anxiety disorder. J Nerv Ment Dis (2006) 1.76
A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety (2008) 1.68
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
Bereavement, complicated grief, and DSM, part 1: depression. J Clin Psychiatry (2010) 1.49
Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry (2014) 1.48
A meta-analysis of the magnitude of biased attention in depression. Depress Anxiety (2010) 1.47
Reducing anxiety sensitivity with exercise. Depress Anxiety (2008) 1.46
D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology (2010) 1.46
Attending to emotional cues for drug abuse: bridging the gap between clinic and home behaviors. Sci Pract Perspect (2007) 1.44
Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD. Psychiatr Serv (2005) 1.43
Cognitive mechanisms of social anxiety reduction: an examination of specificity and temporality. J Consult Clin Psychol (2006) 1.40
Shared Variance among Self-Report and Behavioral Measures of Distress Intolerance. Cognit Ther Res (2011) 1.33
Prevention of missing data in clinical research studies. Biol Psychiatry (2006) 1.32
Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry (2003) 1.31
Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord (2006) 1.28
Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry (2005) 1.28
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther (2011) 1.27
Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am (2010) 1.26
Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry (2013) 1.26
Moderators and non-specific predictors of treatment outcome for anxiety disorders: a comparison of cognitive behavioral therapy to acceptance and commitment therapy. J Consult Clin Psychol (2012) 1.26
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry (2013) 1.26
Does distress tolerance moderate the impact of major life events on psychosocial variables and behaviors important in the management of HIV? Behav Ther (2007) 1.25
Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry (2007) 1.24
The structure of distress following trauma: posttraumatic stress disorder, major depressive disorder, and generalized anxiety disorder. J Abnorm Psychol (2008) 1.24
Emotion dysregulation model of mood and anxiety disorders. Depress Anxiety (2012) 1.22
Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev (2007) 1.22
Let's get physical: a contemporary review of the anxiolytic effects of exercise for anxiety and its disorders. Depress Anxiety (2013) 1.21
Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. J Consult Clin Psychol (2007) 1.21
Resilience: research evidence and conceptual considerations for posttraumatic stress disorder. Depress Anxiety (2007) 1.21
Posttraumatic stress disorder symptoms following media exposure to tragic events: impact of 9/11 on children at risk for anxiety disorders. J Anxiety Disord (2007) 1.19
Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology (Berl) (2005) 1.19
The serotonin transporter gene and risk for alcohol dependence: a meta-analytic review. Drug Alcohol Depend (2010) 1.19
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry (2005) 1.19
A randomized controlled trial of cognitive-behavior therapy for Cambodian refugees with treatment-resistant PTSD and panic attacks: a cross-over design. J Trauma Stress (2005) 1.18
Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord (2002) 1.18
Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry (2005) 1.18
Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther (2003) 1.17
Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. J Psychiatr Res (2012) 1.16
Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry (2004) 1.15
Predicting panic disorder among patients with chest pain: an analysis of the literature. Psychosomatics (2003) 1.15
Oxytocin levels in social anxiety disorder. CNS Neurosci Ther (2008) 1.14
Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord (2004) 1.14
Mediators in the dissonance eating disorder prevention program. Behav Res Ther (2009) 1.12
Anxiety sensitivity: a unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment. Behav Res Ther (2008) 1.12
CBT for Vietnamese refugees with treatment-resistant PTSD and panic attacks: a pilot study. J Trauma Stress (2004) 1.12
Sudden gains during therapy of social phobia. J Consult Clin Psychol (2006) 1.12
Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity. J Consult Clin Psychol (2010) 1.11
Complicated grief and its correlates in patients with bipolar disorder. J Clin Psychiatry (2005) 1.10
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res (2013) 1.09
Prospective evaluation of the effects of anxiety sensitivity and state anxiety in predicting acute nicotine withdrawal symptoms during smoking cessation. Psychol Addict Behav (2011) 1.09
Anxiety sensitivity among Cambodian refugees with panic disorder: A factor analytic investigation. J Anxiety Disord (2006) 1.08
Anhedonia and anxiety sensitivity: prospective relationships to nicotine withdrawal symptoms during smoking cessation. J Stud Alcohol Drugs (2013) 1.08
The panic attack-posttraumatic stress disorder model: applicability to orthostatic panic among Cambodian refugees. Cogn Behav Ther (2008) 1.07
Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res (2012) 1.06